Tisch Multiple Sclerosis Research Center of New York, 521 West 57th Street 4th Fl., New York, NY 10019, USA.
J Neuroimmunol. 2013 Aug 15;261(1-2):123-8. doi: 10.1016/j.jneuroim.2013.05.009. Epub 2013 Jun 22.
Progressive multifocal leukoencephalopathy (PML) is a complication of natalizumab treatment. In order to identify natalizumab-treated patients at risk of developing PML, we assayed for anti-JC virus (JCV) antibody levels in cerebrospinal fluid (CSF). Serial CSF antibody levels were obtained, with 4 patients showing increases in anti-JCV levels indicating possibly viral activation. In patients with both CSF and serum antibody levels, a comparison showed only a moderate Spearman Rank Correlation Coefficient of 0.38. Our data suggests that serum anti-JCV antibody testing alone may not suffice in identifying at-risk patients because of the lack of uniform correlation with CSF titers.
进行性多灶性白质脑病（PML）是那他珠单抗治疗的一种并发症。为了确定发生 PML 风险的那他珠单抗治疗患者，我们检测了脑脊液（CSF）中的抗 JC 病毒（JCV）抗体水平。连续获得 CSF 抗体水平，4 例患者的 JCV 抗体水平升高，提示可能存在病毒激活。在具有 CSF 和血清抗体水平的患者中，比较显示仅存在适度的斯皮尔曼等级相关系数 0.38。我们的数据表明，由于与 CSF 滴度缺乏一致的相关性，单独进行血清抗 JCV 抗体检测可能不足以识别高危患者。
